Why This Patent News Is Big For Bristols Acquisition Of Celgene | Latest News RSS feed

Why This Patent News Is Big For Bristols Acquisition Of Celgene - Latest News


3 Reasons Bristol-Myers' $90 Billion Mega-Merger Makes It A Must Own Stock

Then Bristol would appeal which means that the earliest generic rivals could hit the market is 2021, just one year earlier than the patent expirations. What about the big ... This is why Bristol and ... read more

Bristol-Celgene Deal Opposition Needs a Dose of Reality

(Bloomberg Opinion) -- Whispers of discontent around Bristol-Myers Squibb Co.’s $74 billion acquisition of Celgene Corp. have turned ... but is missing a compelling argument for exactly why that’s the ... read more

Bristol-Myers Squibb's $74 billion acquisition of Celgene would combine two troubled companies

A lack of innovation could be why ... in Celgene's debt, the companies said in an investor presentation. That's a big jump from Bristol's current outstanding long-term obligations of $7.3 billion, ... read more

Looking for another news?


Pfizer Reportedly Rules Out Bristol-Myers Squibb Deal -- Here Are 3 Better Acquisition Targets

Pfizer chairman and CEO Ian Read told Citi analyst Andrew Baum recently that an acquisition of Bristol-Myers Squibb (BMS) is off the table for now, according to financial news ... why Pfizer would be ... read more


Gilead Buys More Galapagos, Callon Acquires Carrizo; Confirming XBI And XOP ETF Strategies

Boeing gets negative coverage, but no new news ... GILD), or Bristol Myers (NYSE:BMY) buying Celgene (NASDAQ:CELG), or even Pfizer (NYSE:PFE) with its recent acquisition of Array BioPharma ... read more

10 Takeover Targets to Watch in 2019

Alexion Pharmaceuticals made a big splash late last ... with a BRCA1/2 alteration. Bristol-Myers Squibb got the biopharma year off to a flying start on January 3 by announcing plans for a $74 billion ... read more

Serious business of cancer sparks Pharma M&A spree

The takeover comes days after US-based Bristol-Myers Squibb said it was buying biotech firm Celgene for $74bn ... of the most important therapy areas for it. So why has there been so much merger and ... read more

Are These The Next Biotech Buyout Targets?

First, it was Bristol ... to be an acquisition target; all this recent news helps to solidify the case. The only company on the list with a single-digit year-to-date return, BeiGene (Nasdaq: BGNE), ... read more

3 Pharma Stocks with No Headache

What set this change in motion was the Bristol-Myers Squibb (BMY) takeover of Celgene (CELG), in a ... with upside sales and potential patent settlement as big catalyst too.” ... read more

JPM recap: Must-reads of the week, from FDA to IPO to M&A and more

Bristol-Myers Squibb and Celgene ... the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the ... read more

Is Biogen a Beat-Up Bargain? And Is Bristol-Myers' Mega-Merger on the Rocks?

Biogen's (NASDAQ:BIIB) bid to reshape Alzheimer's disease treatment was delivered a big blow last week when it decided to bail on its once-promising Alzheimer's drug aducanumab. The news ... if ... read more

10 Takeover Targets to Watch This Fall

“A lot of the big pharmas are looking at strategic ... based on notes to investors and comments in news outlets. For each company mentioned, this list explains where talk of acquisitions has surfaced, ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us